Chemical composition and anti-arthritic activity of *Anacyclus valentinus* extract on adjuvant-induced arthritis in rats

Khadidja Side Larbi 1, Boumediene Meddah 1, Hamza Belkhodja 1, Asmaa Belmimoun 1, Khaled Slimani 2 and Pascal Sonnet 3

1 Bioconversion Research Laboratory, Engineering Microbiology and Health Safety, Faculty of SNV, University of Mascara, Algeria
2 Department of Veterinary Sciences, University of Ibn Khaldoun, Tiaret, Algeria
3 Laboratories of Glucides-Team Thera- FRE-CNRS 3517, Faculty of Pharmacy, University of Picardie, Amiens, France

**Abstract**— *Anacyclus valentinus* L. is a common annual plant in Algeria, known for her various therapeutic effects. In addition, the plant is used as a food condiment. We reported our investigations on the chemical compositions and the antiarthritis activity of methanolic extract of *A. valentinus* (MEAV). The polyphenol extraction by maceration with methanol (80%) gave yields of 17.82%. The identification by LC-MS and colorimetric assays revealed the wealth of methanolic extracts on phenolic compounds including flavonoids (52.15 mg Equ/g) and lactones. Acute oral toxicity of extract was performed in line with OECD guidelines and the lethal dose 50 was assessed greater than 2500 mg/Kg. Regarding the anti-arthritic power, rheumatoid arthritis was induced by Freund’s adjuvant in rats. The methanolic extract of *A. valentinus* presented a largest effect with weight gain, an arthritic score, thymus indices; spleen and serum parameters close to those of the control. The extract also inhibited edema and restored cartilage structure.

**Keywords**— *Anacyclus valentinus*, Arthritis, diclofenac sodium, Freund’s complete adjuvant, paw volume

I. INTRODUCTION

Rheumatoid arthritis (RA) is a chronic and systemic autoimmune joint disease characterized by pain, swelling and inflammation of peripheral joint and destruction of articular tissues and restricted joint movement [1]. RA is one of the most common inflammatory disorders affecting approximately 0.5–1.0% of global adult population [2]. The systemic ramifications of the disease, apart from morbidity and mortality, include cardiopathy, nephropathy, vasculopathy and pulmonary and cutaneous disorders [3]. Conventional medicines used for RA include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biological response modifiers, and corticosteroids [4]. However, these treatments are accompanied by frequently toxicity and severe side effects. Therefore, more patients look for natural agents with relatively less side effects. Plant derived drugs serve as lead molecules to develop more effective and less toxic medicines [5]. *Anacyclus valentinus* is a medicinal plant belonging to the family Asteraceae, locally known as «Guertoufa» [6] and mainly distributed in the Mediterranean basin and in northern Africa [7]. The plant is widely used in folk medicine for treatment of diverse diseases, such as diabetes [8] and cholesterol [9]. *A. valentinus* has an inhibitory effect on bacteria [10] and fungal [11]. It is also used in some parts of the country as a food condiment. Phytochemical studies on plants belonging to the genus *Anacyclus* made known the presence of terpenoids, steroids, coumarin and flavonoids like quercetin and luteolin [12]. Although the plant possesses many potential therapeutic activities in traditional system and containing rich phytochemical constituents, no work has been still done about the anti arthritic activity. Taking these facts into considerations the present study made an attempt to study the chemical composition and to evaluate the anti arthritic activity of methanolic extract of *A. valentinus* against Freund’s complete adjuvant induced arthritis in experimental rats.

II. METHODOLOGY

2.1. Plant material

The areal parts of *Anacyclus valentinus* were collected on October 2013, from local area of El-Bayadh, Algeria. The plant material was identified and authenticated by botanists from Department of Biology, University of Mascara, Algeria. The plant was shade dried powdered in grinder and passed through sieve of mesh size N°40.
2.2. Preparation of extract
10 g of dried powder was macerated with 80% methanol at room temperature for 24 h. The plant residue was re-extracted with addition of 80% methanol, and filtered again after 24 h. Combined filtrates were concentrated by evaporation, dried in desiccator and were stored in airtight containers until usage [13].

2.3. Analysis of extract
2.3.1. Total phenolic content determination (TPC)
The total phenolic content of the extract was determined by the Folin - Ciocaltan method [14]. Briefly 200 μl of the extract was added to 1000 μl of Folin-Ciocalteau reagent (diluted to 10% in distilled water) and 800 μl of sodium carbonate at 7.5 %. The mixture was incubated at room temperature for 30 minutes. The absorbance was measured at 760 nm. Gallic acid in the concentration range of 0-170 μg/ml was used as standard for construction of calibration curve. The total phenolic content was expressed as mg/g in terms of gallic acid equivalents (GAE).

2.3.2. Total flavonoid content determination (TFC)
Aluminum chloride colorimetric method was used for estimation of total flavonoid content [15]. 500 μl of extract was mixed with 1500 μl of distilled water, methanol, 150μl of sodium nitrite (6%). After 5min, 150 μl ml of aluminium chloride (10%) was incorporated and set aside at room temperature for 6 min. The absorbance of the reaction mixture was measured at 510 nm with ultraviolet (UV) visible spectrophotometer. The total flavonoid content was expressed in terms of mg/g in terms of quercetin equivalents (QE).

2.3.3. LC/MS anlysis
The identification of the phenolic compounds from A. valentinus was carried out using liquid phase chromatography coupled with mass spectrometry (LC-MS). The methanolic extract was accurately weighed, and dissolved in methanol. 5.0 μL of sample was injected into Shimadzu LC/MS chromatography equipment. LC-MS analysis was performed on on a Phenomenex Luna 3u C18 column, whith UV detector. The mobile phase consisted of ultra-pure distilled water and acetoniirile. The solvent A consists of 50% water + 50% acetoniirile, while the solvent B is composed of 25% water + 75%. The flow rate was 0.4 mL/min. The column temperature was set at 40 °C.

2.4. Drugs and chemical reagent
Diclofenac sodium was purchased from Pharmacy (Mascara, Algeria). Freund’s complete adjuvant agent

(FCA) (Sigma Aldrich), CRP and FR kits (Spinreact) were obtained from was obtained from the university.

2.5. Animals
Healthy adult male albino rats of Wistar strain "Rattus norvegicus" (weighing 150 – 200 g) were used. The experimental procedures and protocols were carried out in accordance with ethical guidelines. Animals were provided by the Experimental Station of the University of Mascara/Algeria. They were housed under standard conditions of temperature (24 ± 2 °C) with a 12:12 light: dark cycle and relative humidity (50 - 60 %). The animals were given standard diet and water ad libitum.

2.6. Acute toxicity
Acute oral toxicity study of methanolic extract of A. valentinus was performed in line with OECD guideline 423[16].

2.7. Induction of arthritis
Adjuvant arthritis was induced as described by [17]. Briefly, animals were injected intra-plantar with 0.1 ml of Complete Freund’s Adjuvant (CFA) into the left hind paw of each rat. This consists of Mycobacterium butyricum suspended in heavy paraffin oil. Methanolic extract (300mg/Kg) and diclofenac sodium (20mg/Kg) were administered to rats in the various groups. For the comparison, two control groups were used arthritic and non-arthritic controls or vehicle control.

2.8. Drug administration
Two sets of experiments were performed. In the first set of experiments (preventive protocol), the effect of drugs was investigated when given 2h before induction of arthritis. The animals were grouped as follow: Group I: arthritic control; Group II: non-arthritic control (Receiving 10 ml / Kg of sterile physiological water); Group III: treated with diclofenac sodium; Group IV: pre-treated with methanolic extract of A. valentinus (MEAV).

In the second set of experiments, effect of the drugs on established arthritis (curative protocol) was studied. Drugs were administered on day 9 after the induction. The animals were randomly grouped as follow: Group I, Group II and Group III are the same as for the previous test; Group IV*: treated with MEAV.

2.9. Parameter assessment
2.9.1. Paw swelling
The pad thicknesses of the injected paw were measured before and every other day after FCA injection using a calliper. The paw swelling at each time point was expressed as an increase in the footpad thickness (mm)
For groups pre-treated, measurements were taken on the day of induction on the 5th, 10th and 15th day of treatment. While, for animals subjected to curative tests, the thickness of the paw was determined on the day of induction, on the 1st, the 7th and the 15th day of treatment.

2.9.2. Arthritic index
At the end of the experiments, morphological feature of arthritis was monitored, using the criteria as indicated in “TABLE 1” for each animal. The scores for each paw were then added to get the total arthritic index. The average of treated animals is compared with the control group [19].

<table>
<thead>
<tr>
<th>Lesion site</th>
<th>Nature of lesion</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ears</td>
<td>Absence of nodules and ridness</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Presence of nodules and ridness</td>
<td>1</td>
</tr>
<tr>
<td>Nose</td>
<td>No swelling of connected tissue</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Intensive swelling of connected tissue</td>
<td>1</td>
</tr>
<tr>
<td>Tail</td>
<td>Absence of nodules</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Presence of nodules</td>
<td>1</td>
</tr>
<tr>
<td>For paws</td>
<td>Absence of inflammation</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Inflammation at least 1 joint</td>
<td>1</td>
</tr>
<tr>
<td>Hind paws</td>
<td>Absence of inflammation</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Slight inflammation</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Moderate inflammation</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Marked inflammation</td>
<td>3</td>
</tr>
</tbody>
</table>

### Table 1: Shows the scores of arthritic index

2.9.3. Measurement of body weight
The body weight of rats was measured regularly using an analytical balance. The initial weight and final weight of each group were recorded.

2.9.4. Thymus index and spleen index assay
At the end of experiments, the animals were sacrificed and thymus and spleen were promptly removed and weighed. The indexes of thymus and spleen were expressed as the ratio of thymus and spleen wet weight versus body weight (mg/g), respectively [20].

2.9.5. Blood analysis
Blood samples were collected; centrifuged and supernatant serum was collected. Different parameters were estimated like alkaline phosphatase marker for bone destruction (ALP) [21], rheumatoid factor and C-reactive protein marker of inflammation. These latter were measured by latex agglutination method. Values were expressed as IU/l, IU/ml and mg/L respectively.

2.9.6. Radiographic analysis
For radiological studies, the affected paws of experimental rats were removed and preserved in 10% formalin. X-ray images were taken for these paws, and checked for the soft swelling, bony erosions and narrowing of the spaces between joints [22].

2.10. Statistical analysis
All the data are presented as mean ± SD. Statistical analysis was performed with ANOVA. P values below 0.05 (p <0.05) were considered statistically significant.

### III. RESULTS

3.1. Total phenolic content and flavonoid content
Total phenolic and total flavonoid content of the methanolic extract is shown in Table 2. Following the table, MEAV which gave a yield of 17.82 % is very rich in phenolic compounds, especially flavonoids which occupy 45.16% of the totality of the phenolic compounds.

<table>
<thead>
<tr>
<th>Yield (%)</th>
<th>TPC (mg GAE/g)</th>
<th>TFC (mg QE/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.82 ± 0.49</td>
<td>115.47 ± 0.13</td>
<td>52.15 ± 0.78</td>
</tr>
</tbody>
</table>

3.2. LC-MS analysis of MEAV
The chemical composition of MEAV was further investigated by LC-MS analysis (Fig.1, Table 3). The table showed the richness of MEAV in flavonoids. Many compounds have characteristic spectra of flavonols (kaempferol, quercetin, myricetin), flavones (apigenin, luteolin) and flavanols (catechin). These results confirm the colorimetric analysis. The analysis also revealed the presence of derivatives of phenolic acids (sinapic acid, ferulic acid-β-glucoside), sesquiterpenes (lycoperdine) and derivatives of thymol (9,10-dihydroxy-8-methoxy thymol).
3.3. Acute oral toxicity
There was neither change in behavioral pattern or any sign of toxicity during the observations up to 14 days. In addition, no mortality was recorded, the LD50 is therefore assumed to be greater than 2500 mg/Kg (the biological evaluation was carried out at doses between 200 and 2500 mg/kg). We can conclude that MEAV is safe when administered orally.

3.4. Effect of methanolic extract on adjuvant induced arthritis
3.4.1. Paw swelling

Fig. 2: Effect of methanolic extract of A. valentinus (MEAV) on paw swelling

Paw swelling is one of the major factors in evaluating the degree of inflammation and therapeutic efficacy of the drug. Rats injected with FCA (group II) showed a significant increase in paw volume when compared to the normal rats (group I). Pre-treatment with MEAV at the dose of 300 mg/kg inhibited the formation of edema. However, the curative treatment with extract and diclofenac showed a significant reduction in rat paw thickness when compared with the group II (Fig. 2).

3.4.2. Arthritic index
As shown in figure 3, after FCA immunization, the rats showed a significant (P < 0.05) increase of arthritis index. However, pre-treatment and treatment with MEAV at 300mg/Kg and diclofenac at 20 mg/kg significantly diminished the arthritis index compared with FCA group. Noting that, the lowest index was recorded in rats receiving MEAV as a preventive measure.

Table 3: Identification of MEAV by LC-MS

<table>
<thead>
<tr>
<th>Pic N°</th>
<th>m/z</th>
<th>Possible identification</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>266,2</td>
<td>Apigenin</td>
</tr>
<tr>
<td>1</td>
<td>/133,1</td>
<td>malic Acide</td>
</tr>
<tr>
<td>2</td>
<td>/173,0</td>
<td>Ascorbique Acide</td>
</tr>
<tr>
<td>3</td>
<td>/187,0</td>
<td>azelaïque Acide</td>
</tr>
<tr>
<td>4</td>
<td>/189,1</td>
<td>Catechin</td>
</tr>
<tr>
<td>5</td>
<td>/215,0</td>
<td>Lycoperodin 1</td>
</tr>
<tr>
<td>6</td>
<td>/217,0</td>
<td>9,10-dihydroxy-8-methoxy thymol</td>
</tr>
<tr>
<td>8</td>
<td>/225,1</td>
<td>sinapic Acide</td>
</tr>
<tr>
<td>10</td>
<td>/355,1</td>
<td>β-glucosid ferulic Acide</td>
</tr>
<tr>
<td>11</td>
<td>/371,1</td>
<td>Myricetin mono-acetate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Di hydroxy-tetra methoxy flavone</td>
</tr>
<tr>
<td>13</td>
<td>/431,1</td>
<td>Apigenine -7-O- glucoside</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kaempferol -3-O- rhamnoside</td>
</tr>
<tr>
<td>14</td>
<td>/447,0</td>
<td>Luteolin 3-O-β-glucopyranoside</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quercetin 3-O- rhamnoside</td>
</tr>
</tbody>
</table>

Fig. 3: Arthritis index in rats receiving diclofenac and MEAV

www.ijeab.com
3.4.3. Measurement of body weight

The relationship between the extent of joint inflammation and the weight loss were investigated. As shown in figure 4, the average body weights of the rats receiving normal saline (group I) was increased normally with a gain of 13g. On the other hand, a massive and significant weight loss appears in arthritic rats. However, administration of different drugs significantly attenuated body weight loss. They are ranked in descending order as follows: PRE MEAV > CUR MEAV > Diclofenac.

3.4.4. Thymus index and spleen index assay

The index of thymus and spleen was assayed the day of sacrifice. Results report an increase in thymus and spleen index of FCA control group compared to normal control group. There was significantly (< 0.05) reduction of index of thymus and spleen in MEAV treatments groups (Table 4). Diclofenac treatment also significantly decreased the spleen index and thymus index. However, the most important result was registered for MEAV preventive treatment compared with normal group.

Table 4: Effect of MEAV on immune organs in arthritic rats

<table>
<thead>
<tr>
<th></th>
<th>Thymus Index</th>
<th>Spleen Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td>0.683 ± 0.101</td>
<td>2.320 ± 0.212</td>
</tr>
<tr>
<td>FCA</td>
<td>1.295 ± 0.131</td>
<td>3.387 ± 0.151</td>
</tr>
<tr>
<td>Diclofenac</td>
<td>0.839 ± 0.128</td>
<td>2.732 ± 0.237</td>
</tr>
<tr>
<td>PRE MEAV</td>
<td>0.690 ± 0.177</td>
<td>2.478 ± 0.594</td>
</tr>
<tr>
<td>CUR MEAV</td>
<td>0.741 ± 0.117</td>
<td>2.751 ± 0.278</td>
</tr>
</tbody>
</table>

3.4.5. Blood analysis

Table 5 depicts the effect of MEAV on levels of blood marker in arthritic rat serum. A significant increase in the levels of ALP, RF and CRP was observed in arthritic rats. The administration of MEAV (300mg/kg) and diclofenac (20mg/kg) significantly decreased all these parameters compared to FCA control (< 0.05).

Table 5: Effect of MEAV on serum parameters in arthritic rats

<table>
<thead>
<tr>
<th></th>
<th>ALP (UI/L)</th>
<th>RF (UI/ml)</th>
<th>CRP (mg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td>79.65 ± 3.90</td>
<td>8 ± 0</td>
<td>6 ± 0</td>
</tr>
<tr>
<td>CFA</td>
<td>114.17 ± 4.01</td>
<td>57.60 ± 14.31</td>
<td>38.40 ± 13.14</td>
</tr>
<tr>
<td>Diclofenac</td>
<td>93.48 ± 8.10</td>
<td>14.40 ± 10.43</td>
<td>7.20 ± 2.68</td>
</tr>
<tr>
<td>PRE MEAV</td>
<td>77.29 ± 8.44</td>
<td>9.60 ± 3.57</td>
<td>6 ± 0</td>
</tr>
<tr>
<td>CUR MEAV</td>
<td>81.28 ± 6.24</td>
<td>11.20 ± 4.38</td>
<td>7.20 ± 2.68</td>
</tr>
</tbody>
</table>

3.4.6. Radiographic analysis

The radiographic images of the joints of all groups of rats are shown in Fig. 5. The articulation of normal control group presented a normal opacity, joint space and cartilage appeared to be normal. As shown in this figure, it is evident from the radiographic images that adjuvant treated rats (group II) developed periosteal reaction, irregular joint space with opacity essentially concentrated at the level of the femoral condyle. The presence of knee arthritis (inflammation of the knee joint), joint instability and cartilage lysis were also observed. Although diclofenac treatment (group III) reduced inflammation and improved the metabolic function of rats, the radiographic image of joint showed opacity essentially concentrated at the tibial condyle. A lysis of the articular cartilage was also observed. In the extracts pre-treated group (group IV), the joint space appeared normal, no periosteal reaction was observed and joints appeared to be normal. Whereas, a slight bone lysis was determined at the joint of MEAV-treated rats (group IV*). This joint had a radiographic appearance of normal opacity.
rheumatoid cachexia which leads to the decreased physical activity, muscle strength and decreased daily performance [25]. Decrease in body weight was attributed to reduced absorption of $^{14}$C- glucose and $^{14}$C-leucine in rat’s intestine [26]. In the present investigation, the FCA treated rats showed less body weight gain as compared with diclofenac, extract pre-treated and extract treated arthritic rats. Thus, body weight gain may be due to the restoration of the absorption capacity of the intestine. The spleen is a vital organ which serves as the available source of cells and antibody formation, known to be involved in immunological response in adjuvant arthritis. The RA model is an immune hyper-functional model, and marked splenomegaly, and lymphoid hyperplasia were associated with RA [27]. On the one hand, the increase in the weight of the spleen occurs following the release of the cytokines causing a perturbation of the histology of this organ. On the other hand, the variation in thymus weight is due to the suppression or imbalance of the immune system [28]. In the present study, it was found that MEAV significantly decreased the spleen index and thymus index induced by FCA compared with FCA group. This finding suggests that the extract may help in the recovery of the hyper-functioning of immune organs without causing damage. Cytoplasmic cellular enzymes, such as alkaline phosphatase (ALP) are present in the body, but especially in the liver, bone, intestine, kidneys and white blood cells. The cellular localization of these enzymes assigns them a certain activity in the transfer of phosphoric esters through the membranes. They are involved in intestinal absorption and in the ossification process [29]. The attainment of the above-mentioned organs causes the liberation of ALP [30]. A significant ($P < 0.05$) reduction of ALP level was observed after administration of MEAV (300 mg/kg).

Serum rheumatoid factor (RF) is the immunological expression of an individual’s immune system reaction to the presence of an immunoglobulin molecule that is recognized as “non-self.” This response results in the presence of immune complexes. These, in turn, bind complement and may eventually lead to synovium, cartilage, and bone destruction. Higher the levels of serum rheumatoid factor, higher are the development of inflammation [31]. A. valentinus pre-treated and treated animals showed significantly lesser serum RF when compared to disease control animals. Serum RF is an acute-phase protein and has been identified as an important biomarker for various inflammatory and degenerative diseases. The increment of this protein is due to a rise in the plasma concentration of IL-6, which is produced predominantly by macrophages [32]. Freund’s adjuvant induced arthritis rats increased the CRP level as
evidenced in the inflammatory process. A significant (P < 0.05) reduction of CRP level was observed after administration of MEAV, suggested that decreased the inflammatory reactions.

Radiographic changes in RA are useful indicative measures which specify the severity of the disease. Soft tissue swelling, bony erosions and narrowing of joint spaces can be observed [33]. The observed changes in radiographic findings can be attributed to positive benefits provided by the methanolic extract of A. valentinus on the inflammatory mechanisms in the joint tissues.

It is well known that diclofenac had the anti-inflammatory and analgesic activity and often used to cure rheumatoid arthritis. However, this drug only inhibits primary response; do not affect the second response and immune function. In addition, it has obvious side effect and toxicity. Among all tests, the pre-treatment by MEAV proved to be the most effective in chronic inflammation when compared to the other groups. Its action is probably through the inhibition of the production of cyclooxygenase and prostaglandins. The extract, also has an immune-protective effect. In fact, several species of the Asteraceae family are known for their anti-inflammatory effect [34, 35]. These could be attributed to the phenolic constituents present in the plant detected after phytochemical analysis.

Quercetin, myricetin, kaempferol and apigenin identified in the extract have an effect on the synthesis of cyclooxygenase and lipoxygenase [36, 37]. Luteolin 3-O-β-glucopyranoside also identified has an inhibitory effect on the synthesis of thromboxanes and consequently on the synthesis of the main arachidonic acid actor of the pro-inflammatory process [38].

V. CONCLUSION
The results obtained in the present study indicates that phenolic compounds of A. valentinus not only directs towards the control of arthritis progression and/or the inflammation associated with joint synovitis, but also prevents cartilage and bone destruction of the arthritic joints. Extracts of A. valentinus, may have great potential as an alternative to the therapeutic agents currently available for treatment of RA. However, there is need to isolate and characterize the active compounds responsible for the observed anti-arthritic activity.

ACKNOWLEDGEMENTS
The authors wish to thank all the individuals and institutions who made this survey possible.

REFERENCES


